remission induction therapy

remission induction therapy

Oncology Initial chemotherapy administered to a Pt with CA, intended to achieve remission
Mentioned in ?
References in periodicals archive ?
Steroids are an integral part of remission induction therapy in acute lymphoblastic leukemia (ALL) in adults and children.
Although our patient showed complete remission, even after remission induction therapy, there are chances that the cancer might come back.
Schoch et al., "Earlyblast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML cooperative group (AMLCG) 1992 trial," Blood, vol.
Remission Induction Therapy: Standard remission induction therapy for patients with severe disease consists of oral prednisolone and oral cyclophosphamide 2mg/kg/day with monitoring of CBC, renal functions.
These encouraging results led to the initiation of the Phase III study, POLO-AML-2, investigating volasertib in combination with LDAC, in patients aged 65 years and above with previously untreated AML who are ineligible for intensive remission induction therapy.
"The most common treatment approach for AML is intensive remission induction therapy; however, many older patients are ineligible for this approach which involves high doses of chemotherapy which these patients are often unable to tolerate," said Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim.
Since an early blast cell clearance by remission induction therapy is a major independent prognostic factor, the improved outcome in our patients could be related with the initial striking decrease in leukemic cells in the bone marrow and in the extramedullary site obtained with HDMP as a differentiating- and apoptosis-inducing agent.
The effect of short-course high-dose methylprednisolone on peripheral blood CD34+ progenitor cells of children with acute leukemia during remission induction therapy. Turk J Pediatr 2002;44:1-4.
These data suggest that for limited WG, MTX may be as good a choice as CTX as remission induction therapy.
"Based on these data, NanoMed is utilizing Nanotemplate Engineering to develop its lead product which is intended to overcome multidrug resistance in remission induction therapy in elderly acute myelogenous leukemia (AML) patients," Benoit added.
Prednisolone has been used as part of remission induction therapy in early RA and undifferentiated arthritis in IMPROVED study which revealed high percentage of remission rates.